Yuko Oya

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 6

Top Topics

Prognostic Factors

Ejection Fraction

Small Cell Lung Cancer

Top Venues

Cancer research communications

Thoracic cancer

Exploration of targeted anti-tumor therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Makoto Nishio, Shuji Murakami, Hiasto Kawakami, Kyoichi Okishio, Motohiro Tamiya, Haruki Kobayashi, Daichi Fujimoto, Shunichi Sugawara, Toshiyuki Kozuki, Yuko Oya, Hiroki Izumi, Takayuki Shiroyama, Miyako Satouchi, Noboru Yamamoto, Shota Kaname, Daiko Matsuoka, Yohei Otake, Takao Takase, Taro Semba, Koichi Azuma
Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort. Cancer research communications 4 (1) (2024)
Makoto Nishio, Shuji Murakami, Hiasto Kawakami, Kyoichi Okishio, Motohiro Tamiya, Haruki Kobayashi, Daichi Fujimoto, Shunichi Sugawara, Toshiyuki Kozuki, Yuko Oya, Hiroki Izumi, Takayuki Shiroyama, Miyako Satouchi, Noboru Yamamoto, Shota Kaname, Daiko Matsuoka, Yohei Otake, Takao Takase, Taro Semba, Koichi Azuma
Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort. Cancer research communications 4 (1) (2024)
Makoto Nishio, Shuji Murakami, Hiasto Kawakami, Kyoichi Okishio, Motohiro Tamiya, Haruki Kobayashi, Daichi Fujimoto, Shunichi Sugawara, Toshiyuki Kozuki, Yuko Oya, Hiroki Izumi, Takayuki Shiroyama, Miyako Satouchi, Noboru Yamamoto, Shota Kaname, Daiko Matsuoka, Yohei Otake, Takao Takase, Taro Semba, Koichi Azuma
Phase 2 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort. Cancer research communications (2024)
Ken Akao, Yuko Oya, Takaya Sato, Aki Ikeda, Tomoya Horiguchi, Yasuhiro Goto, Naozumi Hashimoto, Masashi Kondo, Kazuyoshi Imaizumi
It might be a dead end: immune checkpoint inhibitor therapy in EGFR-mutated NSCLC. Exploration of targeted anti-tumor therapy 5 (4) (2024)
Takaaki Hasegawa, Hiroaki Kuroda, Noriaki Sakakura, Yozo Sato, Shohei Chatani, Shinichi Murata, Hidekazu Yamaura, Takeo Nakada, Yuko Oya, Yoshitaka Inaba
Novel strategy to treat lung metastases: Hybrid therapy involving surgery and radiofrequency ablation. Thoracic cancer 12 (14) (2021)
Kentaro Ito, Kenta Murotani, Akihito Kubo, Eiji Kunii, Hirokazu Taniguchi, Joe Shindoh, Kazuhiro Asada, Kazuyoshi Imaizumi, Kosuke Takahashi, Masato Karayama, Motoyasu Okuno, Naoki Inui, Osamu Hataji, Sayako Morikawa, Shunsaku Hayai, Takafumi Suda, Takashi Abe, Takeshi Tsuda, Teppei Yamagichi, Tomoki Kimura, Yuko Oya, Tatsuya Yoshida, Toyoaki Hida
Propensity score analysis of overall survival between first- and second-generation EGFR-TKIs using real-world data. Cancer science 111 (10) (2020)